BMED Stock Analysis: Banca Mediolanum | MI
Banks - Regional | MI, Italy | Market Cap: 16.568m EUR | 12M Return: 65.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.1M
EPS Trend: 93.2%
Qual. Beats: 1
Rev. Trend: 86.8%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Banca Mediolanum S.p.A. is an Italian financial services group founded in 1982 and headquartered in Basiglio, offering an integrated range of banking, investment, and insurance products through a single platform. Its offering spans current accounts, deposits, mortgages, personal loans, and payment cards, alongside investment solutions such as mutual funds, unit-linked policies, asset management, trading, social security products, and bond/certificate issues. The group also distributes insurance coverage covering life, health, serious illness, autonomy protection, and home and family risks, and has extended into niche protection lines under its SelfyCare range, including pet veterinary expense reimbursement, travel assistance, and life-project protection.
The company operates within the Italian bancassurance model, a distribution approach widely used in Italy where banking networks sell insurance and asset management products alongside traditional credit services, enabling cross-selling across financial needs. Banca Mediolanum is classified within the GICS Diversified Financial Services sub-industry and is listed on Borsa Italiana (ticker BMED) as a large-cap stock.
- ECB rate path drives net interest margin trajectory
- Wealth management AUM grows on equity market inflows
- Italian sovereign spread widens pressuring bond portfolio
| Net Income: 1.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.89 > 1.0 |
| NWC/Revenue: 25.14% < 20% (prev 45.62%; Δ -20.48% < -1%) |
| CFO/TA 0.00 > 3% & CFO 389.8m > Net Income 1.73b |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 4.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (739.2m) vs 12m ago 0.25% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.77% > 50% (prev 2.81%; Δ -0.04% > 0%) |
| Interest Coverage Ratio: 6.67 > 6 (EBIT TTM 2.46b / Interest Expense TTM 368.9m) |
| A: 0.01 (Total Current Assets 806.6m - Total Current Liabilities 193.1m) / Total Assets 89.9b |
| B: 0.04 (Retained Earnings 3.94b / Total Assets 89.9b) |
| C: 0.03 (EBIT TTM 2.46b / Avg Total Assets 88.0b) |
| D: 0.05 (Book Value of Equity 4.49b / Total Liabilities 85.4b) |
| Altman-Z'' = 0.43 = B |
As of July 08, 2026, the stock is trading at EUR 22.41 with a total of 790,179 shares traded. Over the past week, the price has changed by +2.89%, over one month by +14.13%, over three months by +30.66% and over the past year by +65.22%.
Current recommended Stop Loss: 21.80 (which is 2.7% or 1.5 ATR below the current price).
Banca Mediolanum has no consensus analysts rating.
P/E Trailing = 13.0291
P/E Forward = 11.1111
P/S = 6.7867
P/B = 3.4999
P/EG = 0.2308
Revenue TTM = 2.44b EUR
EBIT TTM = 2.46b EUR
EBITDA TTM = 2.51b EUR
Long Term Debt = 647.1m EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 15.8b EUR (16.6b + (null Debt) - CCE 806.6m)
Interest Coverage Ratio = 6.67 (Ebit TTM 2.46b / Interest Expense TTM 368.9m)
EV/FCF = 45.51x (Enterprise Value 15.8b / FCF TTM 346.4m)
FCF Yield = 2.20% (FCF TTM 346.4m / Enterprise Value 15.8b)
FCF Margin = 14.19% (FCF TTM 346.4m / Revenue TTM 2.44b)
Net Margin = 70.89% (Net Income TTM 1.73b / Revenue TTM 2.44b)
Gross Margin = unknown ((Revenue TTM 2.44b - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.18 (Enterprise Value 15.8b / Total Assets 89.9b)
Interest Expense / Debt = unknown (Interest Expense 368.9m / Debt none)
Taxrate = 17.24% (360.3m / 2.09b)
NOPAT = 2.04b (EBIT 2.46b * (1 - 17.24%))
Current Ratio = 4.18 (Total Current Assets 806.6m / Total Current Liabilities 193.1m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 2.51b)
Debt / FCF = unknown (Net Debt none / FCF TTM 346.4m)
Total Stockholder Equity = 4.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.96% (Net Income 1.73b / Total Assets 89.9b)
RoE = 39.62% (Net Income TTM 1.73b / Total Stockholder Equity 4.37b)
RoCE = 49.05% (EBIT 2.46b / Capital Employed (Equity 4.37b + L.T.Debt 647.1m))
RoIC = 2.77% (EBIT 2.46b / (Assets 89.9b - Curr.Liab 193.1m - Cash 806.6m))
WACC = 8.02% (E(16.6b)/V(16.6b) * Re(8.02%) + (debt-free company))
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 31.46 | Cagr: 0.14%
[DCF] Terminal Value 73.10% ; FCFF base≈646.1m ; Y1≈566.6m ; Y5≈457.8m
[DCF] Fair Price = 9.94 (EV 7.35b - Net Debt 0.0 = Equity 7.35b / Shares 739.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 93.18 | EPS CAGR: 24.29% | SUE: 1.46 | # QB: 1
Revenue Correlation: 86.80 | Revenue CAGR: 22.52% | SUE: 0.59 | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.36 | Chg30d=+6.00% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-06-30): EPS=0.34 | Chg30d=-0.47% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.43 | Chg30d=+1.52% | Revisions=+62% | GrowthEPS=-8.9% | GrowthRev=-33.6%
EPS next Year (2027-12-31): EPS=1.52 | Chg30d=+0.51% | Revisions=+0% | GrowthEPS=+6.2% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +42% (up=7, down=2)